85
Participants
Start Date
March 14, 2024
Primary Completion Date
August 31, 2025
Study Completion Date
October 31, 2029
rAAV2tYF-GRK1-hRPGRco
Adeno-associated virus vector expressing a human RPGR gene
Control
Untreated Control Group 3
Sydney Eye Hospital, Sydney
Royal Victorian Eye & Ear Hospital, East Melbourne
University of Pittsburgh, Pittsburgh
The Center for Advanced Retinal & Ocular Therapeutics University of Pennsylvania Perelman School of Medicine, Philadelphia
Mid Atlantic Retina, Philadelphia
Wilmer Eye Institute at Johns Hopkins, Baltimore
Duke Eye Center, Durham
University of Florida Health Jacksonville, Department of Ophthalmology, Jacksonville
Bascom Palmer Eye Institute- University of Miami, Miami
Cole Eye Institute - Cleveland Clinic, Cleveland
Cincinnati Eye Institute, Cincinnati
Midwest Eye Institute (Retina Partners Midwest), Carmel
Mayo Clinic, Rochester
Retina Foundation of the Southwest, Dallas
Baylor Eye Institute, Houston
Retina Consultants of Texas, Bellaire
Retina Consultants of San Antonio Texas, San Antonio
Retina Macula Institute of Arizona, Scottsdale
Children's Hospital Los Angeles, Los Angeles
Casey Eye Institute, OHSU, Portland
Ophthalmic Consultants of Boston, Boston
Moorfields Eye Hospital, London
The Retina Clinic London, Institute of Ophthalmology, University College London, London
Oxford Eye Hospital, Oxford
Lead Sponsor
Beacon Therapeutics
INDUSTRY